Pierre-Olivier Blotière1, Jérémie Rudant2, Amélie Barré3, Antoine Racine3, Alain Weill1, Laurent Peyrin-Biroulet4, Franck Carbonnel3, François Alla1. 1. French National Health Insurance (CNAMTS), Paris, France. 2. French National Health Insurance (CNAMTS), Paris, France. Electronic address: jeremie.rudant@cnamts.fr. 3. Université Paris Sud and Gastroenterology Unit, Hôpitaux Universitaires Paris Sud, CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France. 4. Inserm U954, Department of Hepato-Gastroenterology, University Hospital of Nancy, Lorraine University, Vandoeuvre-Les-Nancy, France.
Abstract
BACKGROUND: Tumour necrosis factor inhibitors (anti-TNFs) are active but expensive drugs that induce and maintain remission in patients with Crohn's disease (CD) and ulcerative colitis (UC). AIMS: To assess the trends in anti-TNF prescription and the conditions of prescription of these drugs in patients with inflammatory bowel disease (IBD) in France. METHODS: Incidence study of anti-TNF use was performed based on French medico-administrative databases (SNIIRAM/PMSI). IBD patients who initiated adalimumab or infliximab between 2011 and 2013 were selected. RESULTS: The number of new anti-TNF users increased from 4571 to 5875 between 2011 and 2013 (+29%). More specifically, the number of patients not treated with immunosuppressants (IS) during the previous 12 months increased from 2100 to 3007 (+43%), among whom 379 patients in 2011 and 570 patients in 2013 started combination therapy (+50%). These trends were observed for both CD and UC. Patients who were naïve of IS were hospitalised more frequently than those treated with IS prior to anti-TNF therapy. CONCLUSION: This study shows a rapid increase in new prescriptions of anti-TNF for both CD and UC in France between 2011 and 2013. These results suggest a change in medical practices, with anti-TNF agents prescribed more often as first-line maintenance treatment.
BACKGROUND:Tumour necrosis factor inhibitors (anti-TNFs) are active but expensive drugs that induce and maintain remission in patients with Crohn's disease (CD) and ulcerative colitis (UC). AIMS: To assess the trends in anti-TNF prescription and the conditions of prescription of these drugs in patients with inflammatory bowel disease (IBD) in France. METHODS: Incidence study of anti-TNF use was performed based on French medico-administrative databases (SNIIRAM/PMSI). IBDpatients who initiated adalimumab or infliximab between 2011 and 2013 were selected. RESULTS: The number of new anti-TNF users increased from 4571 to 5875 between 2011 and 2013 (+29%). More specifically, the number of patients not treated with immunosuppressants (IS) during the previous 12 months increased from 2100 to 3007 (+43%), among whom 379 patients in 2011 and 570 patients in 2013 started combination therapy (+50%). These trends were observed for both CD and UC. Patients who were naïve of IS were hospitalised more frequently than those treated with IS prior to anti-TNF therapy. CONCLUSION: This study shows a rapid increase in new prescriptions of anti-TNF for both CD and UC in France between 2011 and 2013. These results suggest a change in medical practices, with anti-TNF agents prescribed more often as first-line maintenance treatment.
Authors: B Bokemeyer; M Ghiani; A Fuchs; B Deiters; F Hardtstock; A Brandes; J Knop; H D Orzechowski; T Wilke Journal: Int J Colorectal Dis Date: 2020-05-18 Impact factor: 2.571
Authors: Lauren Folgosa Cooley; James Wren; Mary Kate Keeter; Isaac Lam; Nelson Bennett; Robert E Brannigan Journal: BMC Urol Date: 2020-07-27 Impact factor: 2.264
Authors: Rachael Swann; Alan Boal; Seth Ian Squires; Carly Lamb; Laura Louise Clark; Selina Lamont; Graham Naismith Journal: Frontline Gastroenterol Date: 2019-05-03